Clinical operations
Before Adding Sites, Read the Screen-Failure Log
Separate clinical exclusions, screening logistics and operational delays before choosing how to address enrollment problems.
By Lampgen Clinical Research

3 min read · estimated
What the source reported
FDA finalized guidance on laboratory-value eligibility criteria and washout periods and concomitant medications in July 2026. The documents support trial-specific scientific justification and caution against unnecessary restrictions. [1, 2] They do not authorize sites to waive the approved eligibility criteria. Eligibility safeguards and appropriate clinical judgment remain essential to participant protection.
What this means for trial teams
Lampgen’s analysis: an enrollment shortfall is an outcome with several possible explanations. More sites may be appropriate when geography, patient availability or site capacity limits access. But additional sites will not necessarily resolve a barrier repeated throughout the existing screening pathway. Review what is actually preventing enrollment before selecting the intervention.
Start by agreeing on definitions. A patient identified for possible discussion is different from someone who consented to screening, and both differ from a person who completed eligibility review. Use the study’s definitions and permitted data sources. Do not combine incompatible denominators into a single screen-failure rate or interpret an unrecorded reason as a clinical exclusion.
Then examine the reasons. Separate failure of a protocol criterion from an incomplete test, a result arriving outside a window, a withdrawn decision to participate or an operational delay. A patient may have more than one relevant barrier, so describe how the analysis handles multiple reasons. Protect personal information and avoid creating unnecessary identifiable lists outside approved systems.
Look for patterns across sites and over time. Does the same laboratory threshold recur? Are prior-treatment timelines difficult to document? Is a central result frequently unavailable at the decision point? Those observations suggest different questions for medical, laboratory, operational or protocol-design colleagues. They do not, on their own, prove that a criterion is inappropriate.
Use a focused review meeting. Bring a clear description of the barrier, its frequency within a defined group, the clinical context and any missing information. Ask the people authorized to evaluate the criterion or process what options are justified. The response may involve better instructions, a workflow repair, additional sites or consideration of an amendment through the required review pathway.
Suppose, hypothetically, several potential participants cannot complete a required test within the specified screening period. The first task is to understand why: appointment availability, collection timing, specimen adequacy and report routing have different remedies. Removing a requirement without scientific review would not be an acceptable substitute for that investigation.
The significance extends beyond recruitment efficiency. A well-understood screening pathway can reveal who reaches a trial discussion, who faces avoidable delays and which questions should inform future protocol planning. Any equity analysis needs appropriate data, meaningful denominators and careful interpretation. A small site-level pattern is a reason to investigate, not a basis for a sweeping population claim.
Lampgen recommends that CRAs capture recurring barriers clearly and that CTMs connect them to the correct decision owners. The practical objective is to select a response matched to the problem. Before expanding the funnel, understand what happens to people already entering it.